
resilience in the first half of 2025 despite a challenging market
environment. While total revenue declined 13% year-on-year
to $18.9 million for the financial period ending 30 June 2025,
the company maintained momentum in its core business, with
processing assemblies and instrument sales growing 9% and 22%
respectively. Although Strategic Platform License ("SPL") revenue
soſtened due to customer reprioritisation, MaxCyte added three
new SPL clients, reinforcing its long-term commercial pipeline.
The acquisition of SeQure Dx expanded its capabilities in gene
editing, and cost optimisation efforts, including reduced sales and
marketing spend, were implemented to preserve cash.
Aurrigo International
(1.8% of net assets, -£2.7 million) is a leading
provider of highly specialised autonomous transport solutions,
which are predominately aimed at the aviation ground handling
industry. Aurrigo’s patent protected autonomous vehicles promise
more efficient baggage transportation to and from aircraſt,
thereby reducing labour reliance and minimising the frequency
and severity of accidents. Aurrigo delivered mixed financial
results for the first six months ending 30 June 2025, with revenue
declining slightly to £3.5 million down from £3.9 million year-on-
year, primarily due to soſtness in the Automotive division linked
to US tariff disruptions. However, the Autonomous division grew
41% year-on-year to £1.1 million, reflecting strong commercial
traction and strategic progress. Gross margin improved to 42.3%,
up from 35%, driven by a favourable sales mix. While the adjusted
EBITDA loss widened to £1.6 million, the company remains
well-capitalised following a successful £14.1 million fundraise.
Operational highlights included the launch of Auto-Cargo® with
UPS, a strategic partnership with Swissport, and formal approval
from Schiphol Group for its Auto-DollyTug® and Auto-Sim®
platforms. With a strong balance sheet, expanding commercial
pipeline alongisde increasing global recognition, Aurrigo is
well-positioned to scale its autonomous technology offerings
and deliver long-term value despite near-term challenges in its
automotive division.
Incanthera
(0.1% of net assets, -£2.6 million) is a UK-based
dermatology company focused on discovering and developing
targeted skin treatments. Results for the year ended 31 March
2025 reflected a year of strategic progress with some financial
challenges. The company achieved its first revenues from the
launch of its Skin+CELL luxury skincare range in August 2025,
supported by a direct-to-consumer campaign and positive early
customer feedback. Incanthera maintained tight cost controls
during the period and strengthened its cash position through
a £0.5 million institutional fundraise in June 2025. Post-year-
end, the company raised an additional £3.3 million to support
inventory scale-up. Although initial financial performance was
disappointing the company successfully protected its intellectual
property during the period, and demonstrated proof of concept
for its formulation technology. With further product development
underway and new market channels being explored, Incanthera
enters the coming financial year with renewed commercial
momentum and a clear focus on expanding its presence in the
global skincare and therapeutic markets.
Tracsis
(3.4% of net assets, -£2.3 million) is a technology and
soſtware business with two operating divisions; rail technology
and traffic and data services. Tracsis provides automated resource
scheduling soſtware to international transport markets which
help optimise labour schedules. Other solutions include smart
ticketing and automated ‘train delay repayment’ soſtware to
enhance
customer
experiences. The
company
delivered
a
resilient performance in 2025, with revenue rising modestly to
£81.9 million and adjusted EBITDA holding steady at £12.6 million,
despite well-flagged headwinds in the UK rail sector. The first half
was impacted by market wide spending constraints in UK rail, a
cyberattack on a major customer and inflationary pressures in
the Traffic Data & Events division. However, the second half saw
some improvement in trading, supported by growth in recurring
soſtware and transactional revenues, and delivery of a strong
Rail Technology & Services orderbook. The company ended the
year with £23.4 million in cash, completed a £3.0 million share
buyback, and secured a new £35 million revolving credit facility
to support future investment. While profitability was flat year-
on-year, Tracsis made strategic progress with digital ticketing
trials, international deployments, and multi-year contract wins,
positioning the business for long-term growth despite near-term
market challenges.
Futura Medical
(0.1% of net assets, -£1.8 million) is a UK-
based
pharmaceutical
company
focused
on
the
research,
development, and commercialisation of innovative sexual health
treatments. Futura Medical is best known for its proprietary
topical formulations, such as Eroxon®, which offer clinically
proven, fast acting, and non-invasive alternatives to conventional
therapies. The company reported a challenging first six months
ending 30 June 2025, with revenue declining to £1.0 million from
£7.0 million in the prior year. This was primarily due to slower-
than-expected in-market sales of Eroxon®, particularly in the U.S.,
where initial 2024 inventory orders continued to meet demand,
suppressing replenishment sales. Despite this, the company
maintained a cash balance of £3.69 million and is progressing
development of its pipeline products, Eroxon® Intense and
WSD4000. A strategic review was launched in August to evaluate
cost structures and commercial priorities, with a cost-cutting
programme now underway. Although 2025 revenue is expected
to fall materially below expectations, the Board remains confident
in the long-term value of its assets and continues to explore
strategic options, including potential partnerships and asset sales,
to enhance shareholder value.
Investment Manager’s Review
(continued)
12
Unicorn AIM VCT plc
|
Annual Report
|
2025
Strategic Update
Governance
Independent Auditor's Report
Financial Statements
Information